Acceleron to Webcast First Quarter 2021 Financial Results on May 6, 2021
Acceleron Pharma (Nasdaq:XLRN) will host a webcast and conference call on May 6, 2021, at 5:00 p.m. EDT to discuss its Q1 2021 financial results. The event will be accessible through the Company's website under 'Events & Presentations.' Acceleron focuses on developing therapies for serious diseases, notably pulmonary arterial hypertension (PAH) and blood disorders. The company reported positive results from the PULSAR Phase 2 trial for sotatercept, which aims to serve as a backbone therapy for PAH. Additionally, REBLOZYL is recognized as the first erythroid maturation agent approved in multiple regions.
- Positive topline results from the PULSAR Phase 2 trial for sotatercept in PAH.
- Plans for multiple Phase 3 trials to establish sotatercept as a backbone therapy for PAH.
- REBLOZYL is approved in the US, Europe, and Canada for treating anemia in specific blood disorders.
- None.
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 6, 2021 at 5:00 p.m. EDT to discuss its first quarter 2021 financial results.
The webcast will be accessible under "Events & Presentations" in the Investors & Media page of the Company’s website at www.acceleronpharma.com. To participate in the conference call, please dial 833-494-1483 (domestic) or 236-714-2620 (international) and reference code #5559908.
An archived version of the webcast will be available for replay on the Company’s website for approximately one year.
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Acceleron focuses its research, development, and commercialization efforts in pulmonary and hematologic diseases. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial. The Company is currently planning multiple Phase 3 trials with the potential to support its long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease. Acceleron is also investigating the potential of its early-stage pulmonary candidate, ACE-1334, which it plans to advance into a Phase 1b/Phase 2 trial in systemic sclerosis-associated interstitial lung disease (SSc-ILD) this year.
In hematology, REBLOZYL® (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the United States and are also developing luspatercept for the treatment of anemia in patient populations of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005098/en/
FAQ
What are Acceleron Pharma's Q1 2021 financial results?
What is the significance of the PULSAR Phase 2 trial results for XLRN?
When will the conference call for XLRN's financial results take place?
Where can I access the webcast for Acceleron Pharma's Q1 2021 results?
